Alto Neuroscience, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Alto Neuroscience, Inc. (ANRO) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.78M.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $4.13M, a 144.09% increase year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$656.00K.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$628.00K.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$101.00K, a 121.81% decline from fiscal 2024.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $463.00K.
- Alto Neuroscience, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$291.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.35M 10-Q · filed 2026-08-12 | $1.70M derived: sum of 3 quarters · filed 2026-08-12 | $1.07M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $4.13M 10-Q · filed 2026-05-13 | $3.47M derived: sum of 2 quarters · filed 2026-05-13 | $2.85M derived: sum of 3 quarters · filed 2026-05-13 | $2.34M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | -$656.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.28M derived: sum of 2 quarters · filed 2026-03-16 | -$1.79M derived: sum of 3 quarters · filed 2026-08-12 | -$101.00K 10-K · filed 2026-03-16 | |||
| 2025-09-30 | -$628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.14M derived: sum of 2 quarters · filed 2026-08-12 | $555.00K 10-Q · filed 2025-11-12 | $105.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | -$509.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.18M 10-Q · filed 2026-08-12 | $733.00K derived: sum of 3 quarters · filed 2026-08-12 | -$11.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-13 | $1.24M derived: sum of 2 quarters · filed 2026-05-13 | $498.00K derived: sum of 3 quarters · filed 2026-05-13 | $374.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | -$450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.19M derived: sum of 2 quarters · filed 2026-03-16 | -$1.32M derived: sum of 3 quarters · filed 2026-03-16 | $463.00K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$744.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$868.00K derived: sum of 2 quarters · filed 2025-11-12 | $913.00K 10-Q · filed 2025-11-12 | $921.00K 10-Q · filed 2024-11-12 | $463.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.66M 10-Q · filed 2025-08-13 | $1.67M 10-Q · filed 2024-08-13 | $1.21M derived: sum of 3 quarters · filed 2025-08-13 | $1.29M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.78M 10-Q · filed 2025-05-14 | $1.79M 10-Q · filed 2024-05-14 | $1.33M derived: sum of 2 quarters · filed 2025-05-14 | $1.41M derived: sum of 3 quarters · filed 2025-05-14 | $1.03M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$368.00K derived: sum of 2 quarters · filed 2025-03-20 | -$755.00K derived: sum of 3 quarters · filed 2025-03-20 | -$291.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$305.00K derived: sum of 2 quarters · filed 2024-11-12 | $159.00K 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $77.00K 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | $464.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |